KU Innovation Park’s newest cohort of its Lab2Market accelerator program is underway. Nine researchers from across the Kansas City region are participating in the six-month program to drive their discoveries from the lab to the marketplace. The cohort receives benefits like access to dedicated space at KU Innovation Park, free business services, monthly sessions on relevant topics, access to a community of innovators and more.
“The Lab2Market accelerator helps researchers turn groundbreaking ideas into real-world solutions,” said Chris Rehkamp, the Park’s director of business services. “By providing the right support and expertise, we hope to make it easier for innovators to bring their technologies to market. That’s at the heart of the Park’s mission.”
The participants of the 2025 cohort include:

Todd Bradley – Director of Immunogenomics, Genomic Medicine Center, Children’s Mercy Kansas City; Associate Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Assistant Professor of Pediatrics and Pathology, University of Kansas Medical Center
Bradley and his team are analyzing the components of human milk to provide personalized insights and solutions to promote optimal growth, development and lifelong health.

Jonathan Brumberg – Chairperson and Professor, Department of Psychology, University of Kansas
Brumberg’s group is working on improving eye-based access methods to augmentative and alternative communication devices and other assistive technology.

Emily Law – Professor & Vice Chair for Research, Department of Pediatrics, Psychiatry & Behavioral Sciences, University of Kansas Medical Center
Law and her team developed Firefly, a web-based program that delivers cognitive-behavioral therapy for insomnia (CBT-I) to help adolescents improve their sleep, and they are now creating Firefly 2.0, a mobile-friendly and engaging version designed with teens to increase accessibility and effectiveness.

Jackob Moskovitz – Associate Professor, Department of Pharmacology & Toxicology at the University of Kansas School of Pharmacy
Moskovitz’s team is developing a vaccine that could help prevent and slow the progression of Alzheimer’s disease by reducing key disease markers and improving cognitive function in preclinical models.

Amber Rowland – Associate Research Professor at the University of Kansas Center for Research on Learning and the Achievement and Assessment Institute
Rowland and her team developed VOISS, a virtual reality platform that helps students with autism practice real-world social skills in a safe, immersive environment.

Yezan Salamoun, PharmD – Graduate Student Researcher and Ph.D. Candidate in Pharmaceutical Chemistry, University of Kansas
Salamoun, a researcher in Dr. Michael Hageman’s lab, is developing an oral testosterone therapy that starts as an inactive compound and activates in the body, aiming to improve effectiveness and convenience for patients.

Jennifer Villwock, MD, FAAOA – Vice Chair for Research, Otolaryngology-Head and Neck Surgery; Professor, Otolaryngology-Head and Neck Surgery at University of Kansas Medical Center
Villwock and her team have created BetterSpec, a redesigned speculum that uses advanced endoscopic imaging and a slimmer, more flexible design to make gynecological exams more comfortable, while improving visibility and enabling remote assessments and digital health applications.

Liang Xu – Professor, Department of Molecular Biosciences, University of Kansas
Xu and his team have developed a new class of cancer-fighting drugs targeting a key protein linked to drug resistance, the oncoprotein HuR, potentially improving chemotherapy and immunotherapy effectiveness.

Michael Wang – Professor, Department of Pharmaceutical Chemistry, University of Kansas
Wang is developing new therapies to mitigate the health risks associated with PFAS, known as “forever chemicals,” and a portable device for PFAS environmental monitoring.
The cohort started meeting in January and will meet monthly through June. The program is funded by a Build to Scale grant from the U.S. Economic Development Agency (EDA). To learn more about the Park’s Lab2Market accelerator, click here.